MassDevice

The Medical Device Business Journal — Medical Device News & Articles | MassDevice

Home » Diabetes: GI Dynamics spikes on 1st Australian EndoBarrier implants

Diabetes: GI Dynamics spikes on 1st Australian EndoBarrier implants

By

GI Dynamics logo

The 1st group of Australian patients received GI Dynamics‘ (ASX:GID) EndoBarrier obesity and Type II diabetes treatment device this week at the company’s newly established center in Melbourne.

The news sent GID shares up 6.7% to $1.11 as of about 3:30 p.m. today.

"This is an important milestone for our company and for clinicians and patients in Australia, who now have access to a new, non-surgical treatment option for Type II diabetes and/or obesity," president & CEO Stuart Randle said in prepared remarks.

The patients were treated at the Epworth Centre for Bariatric Surgery, which last month became GI Dynamic’s 1st Center of Excellence for its flagship EndoBarrier gastrointestinal liner.

The EndoBarrier is a plastic gut-lining sleeve that hangs from the outlet of the stomach and lines the small intestine. It’s designed to slow the uptake of nutrients to effect weight loss, and has been shown in small clinical trials to also mitigate the symptoms of diabetes.

The device, which is on the market in the U.K., Netherlands, Austria, Germany and Chile, has been reviewed in 13 clinical trials across more than 500 patients, according to a press release.

GI Dynamics said it’s hoping this year to begin clinical trials of its EndoBarrier gastrointestinal liner in the U.S., launch commercial sales "in a select number of new countries," and add more Centers of Excellence.

The company went public in September 2011, netting nearly $80 million (A$74 million) in an initial public offering on the Australian stock exchange.

In case you missed it

RSS From Medical Design & Outsourcing

  • How Bigfoot Biomedical plans to take diabetes management forward
    For close to 20 years, Jeffrey Brewer has focused on finding ways to support insulin delivery and manage diabetes. Bryan Mazlish was the first person in the world to hack into an insulin pump and continuous glucose monitor (CGM) and enable a do-it-yourself closed-loop insulin dosing system, Brewer told Drug Delivery Business News. “It turned… […]
  • Edwards Lifesciences misses on Q4 earnings as omicron hammers hospitals
    Edwards Lifesciences (NYSE:EW) posted fourth-quarter results that fell short of the consensus forecast on Wall Street, but reaffirmed its outlook for 2022. The Irvine, California-based heart device company yesterday evening reported profits of $335.3 million — or $0.53 per diluted share — on sales of $1.33 billion for the three months ended Dec. 31, 2021,… […]
  • How Phillips-Medisize helped Sotech Health develop a breath analyzer for COVID-19
    Medtech contract manufacturing giant Phillips-Medisize used its human-factors product design expertise to help startup Sotech Health create what the companies claim is a breath sensor system that can detect COVID-19 in less than 30 seconds. Dallas-based Sotech Health has submitted the device to the FDA for an emergency use authorization. It’s also seeking regulatory nods… […]
  • Carbon introduces next-gen 3D printers
    Carbon today announced its next-gen M-Series 3D printers based on DLS technology. The new M3 and the M3 Max printers boast faster printing, a more straightforward print experience, expanded design space and a more consistent surface finish, according to Carbon. Carbon said a 4K light engine enables a doubling of the build area with the… […]
  • Philips launches at-home, 12-lead ECG for clinical trials
    Royal Philips (NYSE: PHG, AEX: PHIA) announced today that it is expanding its remote cardiac monitoring portfolio with a patch-based, clinical-grade ECG. The new at-home electrocardiogram monitors could reduce the need for site visits during clinical trials, according to the Dutch medtech giant. At-home ECG is a hot space: iRhythm Technologies CEO Quentin Blackford recently… […]
  • TE Connectivity beats the Street in Q1
    TE Connectivity (NYSE:TEL) posted first-quarter results today that beat the consensus forecast on Wall Street. The Schaffhausen, Switzerland–based company provides connectivity and sensor solutions for a broad range of industries, including medtech. The company reported profits of $566 million — or $1.72 per share — on sales of $3.8 billion for the fiscal quarter ended… […]
  • Element Materials Technology acquired by Temasek
    Element Materials Technology this week announced that it was acquired by Bridgepoint’s Temasek for an undisclosed amount. Singapore-based Temasek has been a majority shareholder in Element since 2019. Element expects to accelerate its growth and build stronger positions in end-markets like life sciences and connected technologies, according to the company. “The acquisition of Element by… […]
  • FDA approves Medtronic’s spinal cord stimulation for chronic pain from diabetic neuropathy
    Medtronic (NYSE:MDT) announced today the FDA approved its Intellis and Vanta neurostimulator for treating chronic pain. The approval covers the Intellis rechargeable neurostimulator and the Vanta recharge-free neurostimulator for the treatment of chronic pain associated with diabetic peripheral neuropathy. Get the full story at our sister site, MassDevice. The post FDA approves Medtronic’s spinal cord stimulation […]
  • ‘Itty bitty’ falloposcope imaging device used inside fallopian tubes for the first time
    After years of development, University of Arizona researchers have captured their first images inside fallopian tubes with a new device that could be used to search for early signs of ovarian cancer. University of Arizona BIO5 Institute Director Jennifer Barton developed the high-resolution falloposcope, which has a diameter of only 0.8 mm. “It’s itty bitty,”… […]
  • Hantel appoints VP of business development
    Hantel recently announced that it appointed Ron Balogh as VP of business development. The Hayward, California-based medtech design and contract manufacturing company appointed Balogh on Jan. 3. He will be responsible for serving the company’s current clients and growing the company by improving communications and its presence within the industry. Get the full story on… […]
  • iRhythm plans silent AFib screening pilots, high-level hires and Zio Watch evaluations
    iRhythm Technologies (NSDQ:IRTC) has big plans for 2022 and its remote external electrocardiogram monitors as the medical device developer gears up for growth. President and CEO Quentin Blackford is looking to hire an international general manager among other roles in the coming months, he told Medical Design & Outsourcing after presenting at this month’s 2022… […]

Leave a Reply